

Title: Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients

Andrew H. Karaba, MD, PhD^{1*} (ORCID 0000-0003-2785-317X), Jake D. Kim, BA^{2*} (ORCID 0000-0002-7667-8075), Teresa P-Y Chiang, MD, MPH² (ORCID 0000-0003-0601-7420), Jennifer L. Alejo, MD² (ORCID 0000-0003-3137-9271), Aura T. Abedon, BS² (ORCID 0000-0001-8083-6964), Jonathan Mitchell, MBBS² (ORCID 0000-0003-0418-3636), Amy Chang, MD² (ORCID 0000-0002-9167-518X), Yolanda Eby, MS³, Trevor Scott Johnston, BS¹, Tihitina Aytenfisu, BA¹, Casey Hussey, MS³, Alexa Jefferis, BS² (ORCID 0000-0002-7222-5618), Nicole Fortune, BS² (ORCID 0000-0001-7371-554X), Rivka Abedon² (ORCID 0000-0003-2270-1580), Letitia Thomas² (ORCID 0000-0002-6323-2285), Daniel S. Warren, PhD² (ORCID 0000-0002-1370-466X), Ioannis Sitaras, PhD⁴, Andrew Pekosz, PhD⁴ (0000-0003-3248-1761), Robin K. Avery, MD¹ (ORCID 0000-0001-7692-3619), Allan B. Massie, PhD, MHS^{2,5,6} (ORCID 0000-0002-5228-5125), William A. Clarke, MD³ (0000-0001-9665-4786), Aaron A.R. Tobian, MD, PhD³ (ORCID 0000-0002-0517-3766), Dorry L. Segev, MD, PhD^{2,5,6} (ORCID 0000-0002-1924-4801), William A. Werbel, MD¹ (ORCID 0000-0003-2943-5895)

*AHK and JDK contributed equally

(1) Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore MD

(2) Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore MD

(3) Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD

(4) Department of Molecular Microbiology and Immunology, Johns Hopkins University
Bloomberg School of Public Health, Baltimore, MD

(5) Department of Surgery, NYU Grossman School of Medicine, New York, NY

(6) Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD

KEYWORDS: COVID-19, monoclonal antibody, Tixagevimab, Cilgavimab, organ transplant

WORD COUNT: 1912 words

ABSTRACT: 191 words

Contact Information:

William A. Werbel, M.D.

Assistant Professor, Department of Medicine

2000 E. Monument St

Baltimore, MD 21205

Tel: 410-614-0648

wwerbel1@jhmi.edu

Abbreviations:

150+150mg T+C - 150mg Tixagevimab and 150mg Cilgavimab

300+300mg T+C - 300mg Tixagevimab and 300mg Cilgavimab

Anti-N - anti-nucleocapsid

AU - arbitrary units

BAU - binding antibody units

EIA – Enzyme Immunoassay

FDA - US Food and Drug Administration

IQR – interquartile range

MMF – mycophenolate

mRNA – messenger RNA

MSD - Meso Scale Diagnostics (MSD)

PrEP - pre-exposure prophylaxis

RBD – Receptor Binding Domain

SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2

SOTR - solid organ transplant recipients

T+C – Tixagevimab and Cilgavimab

ULOQ – upper limit of quantification

VOC - variants of concern (VOC)

Abstract:

Neutralizing antibody responses are attenuated in many solid organ transplant recipients (SOTRs) despite SARS-CoV-2 vaccination. Pre-exposure prophylaxis (PrEP) with the monoclonal antibody combination Tixagevimab and Cilgavimab (T+C) might augment immunoprotection, yet activity against Omicron sublineages in vaccinated SOTRs is unknown. Vaccinated SOTRs who received 300+300mg T+C (either single dose or two 150+150mg doses) within a prospective observational cohort submitted pre- and post-injection samples between 1/10/2022-4/4/2022. Binding antibody (anti-receptor binding domain [RBD], Roche) and surrogate neutralization (%ACE2 inhibition; $\geq 20\%$ connoting neutralizing inhibition, Meso Scale Discovery) were measured against variants including Omicron sublineages BA.1 and BA.2. Data were analyzed using the Wilcoxon matched-pairs signed-rank test and McNemar's test. Among 61 participants, median (IQR) anti-RBD increased from 424 (IQR <0.8-2322.5) to 3394.5 (IQR 1403.9-7002.5) U/ml post T+C ($p < 0.001$). The proportion demonstrating vaccine strain neutralizing inhibition increased from 46% to 100% post-T+C ($p < 0.001$). BA.1 neutralization was low and did not increase (8% to 16% of participants post-T+C, $p = 0.06$). In contrast, BA.2 neutralization increased from 7% to 72% of participants post-T+C ($p < 0.001$). T+C increased anti-RBD levels, yet BA.1 neutralizing activity was minimal. Encouragingly, BA.2 neutralization was augmented and in the current variant climate T+C PrEP may serve as a useful complement to vaccination in high-risk SOTRs.

1. Introduction:

Many solid organ transplant recipients (SOTRs) exhibit poor binding antibody response and plasma neutralizing capacity against SARS-CoV-2 variants of concern (VOC) despite repeated vaccine doses¹⁻³. This, in part, underlies higher rates of clinically significant infection after vaccination (“breakthrough”) in SOTRs^{4,5}, and recommendations for additional vaccine doses. The injectable monoclonal antibody combination Tixagevimab and Cilgavimab (T+C) was recently authorized by the US Food and Drug Administration (FDA) as pre-exposure prophylaxis (PrEP) versus SARS-CoV-2, a complementary strategy to reduce COVID-19 in immunocompromised persons⁶. Supporting data, however, were based on trials of unvaccinated, immunocompetent persons and preceded the rise of the Omicron variant and its sublineages, which exhibit significant immune evasion^{7,8}. Indeed, *in vitro* data indicated a >100-fold decrease in neutralization of BA.1 and supported doubling of the recommended dose of T+C from 150+150mg (150mg Tixagevimab and 150mg Cilgavimab) to 300+300mg (300mg Tixagevimab and 300mg Cilgavimab)⁹. Due to uncertainty regarding the protection afforded by T+C, we analyzed anti-spike receptor binding domain (RBD) antibody responses and plasma neutralizing capacity against VOC including Omicron sublineages as well as tolerability in a real-world observational cohort of vaccinated SOTRs.

2. Methods

2.1 Cohort

SOTRs were enrolled in a national, prospective observational study of SARS-CoV-2 vaccine response (Johns Hopkins IRB00248540) as previously described^{10,11}. All participants were

contacted in January 2022 to report prior or planned receipt of T+C (150+150mg dose), with a second communication in March 2022 to capture receipt of 300+300mg dosing (either as two 150+150mg doses or one as 300+300mg dose) following revised FDA recommendations. Participants were enrolled and consented electronically. All participants receiving a total of 300+300mg dosing (i.e., full dose) between January 10 and April 4, 2022 were included in this analysis (n=61). The study team neither administered T+C nor encouraged its receipt, and the doses were independently administered in the community. Participants were stratified by history of recent SARS-CoV-2 antigen exposure, defined as vaccination between 30 days prior to first T+C injection and first post-T/C sample collection date, or SARS-CoV-2 infection between 90 days prior to first T+C injection and first post-T/C sample collection date, as this may have confounded changes in immunogenicity measurements.

2.2 Sample collection and processing

Participants provided whole blood samples via at-home phlebotomy service ≤ 2 weeks before and two weeks following each T+C dose. Blood was collected in 8.5mL acid citrate dextrose tubes and shipped overnight to the study team (Johns Hopkins University). Plasma was separated via centrifugation and stored at -80°C .

2.3 Binding antibody measurements

Plasma samples were tested on two anti-spike assays (one clinical, one research) given *a priori* uncertainty regarding the capture of the monoclonal antibody product. This included the clinical Roche Elecsys anti-SARS-CoV-2-S anti-receptor binding domain (RBD) pan

immunoglobulin assay (units/mL, approximately 1:1 with World Health Organization binding antibody units [BAU]). Samples with anti-RBD >250 U/mL were successively diluted until signal fell within quantification range. Additionally, the Meso Scale Diagnostics (MSD, Rockville, MD) research assay was used to measure anti-RBD and anti-nucleocapsid (anti-N) binding antibody via the V-PLEX COVID-19 Respiratory Panel 3 Kit at 1:5000 dilution per manufacturer's protocol. Plates were read on a MESO QuickPlex SQ 120 and arbitrary units (AU) were calculated using the MSD Discovery Workbench software according to the manufacturer's protocol. Conversion to WHO binding antibody units (BAU) was done by multiplying by the manufacturer's recommended conversion factor. The upper limit of quantification (ULOQ) for MSD anti-RBD assay is 4500 BAU. The imputed value from the manufacturer's software was used if a signal was above ULOQ.

2.4 Surrogate neutralization (percent ACE2 inhibition)

The MSD chemiluminescent assay was used to measure the inhibition of ACE2 receptor binding to the spike protein (%ACE2 inhibition) as previously described³. Samples were assayed on MSD SARS-CoV-2 panel 25 at a dilution of 1:100 and tested against the ancestral strain (vaccine), B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), BA.1 (Omicron), and BA.2 (Omicron). Based on prior work in SOTRs utilizing authentic live virus assays, $\geq 20\%$ ACE2 inhibition was defined as "neutralizing inhibition" given the consistent association with live virus neutralizing capacity in this specific immunosuppressed population³.

2.5 Statistical analysis

Wilcoxon matched-pairs signed-rank test was used to compare the anti-RBD level pre- and post-T+C. McNemar's test was used to compare the frequency of achieving neutralizing inhibition ($\geq 20\%$) pre- and post-T+C. Analyses were repeated for the pre-specified subgroup without recent SARS-CoV-2 antigen exposure. For SOTRs receiving two 150+150mg doses of T+C, the longitudinal trajectory of anti-RBD and %ACE2 inhibition were measured after each dose to quantify the effect of a second 150+150mg dose. The correlation between the log₁₀-transformed clinical and research assays, as well as the clinical assay and percent ACE2 inhibition were examined using Spearman's rank correlation coefficients¹². Scatterplots of % ACE2 inhibition versus anti-RBD were visualized to assess potential thresholds associated with neutralizing inhibition, by variant. Analyses were conducted on Stata/SE 17.0 (College Station, TX) and Microsoft Excel (2019).

2.6 Safety assessments

Participants received electronic surveys 7 days following each T+C injection to solicit adverse events, specifically querying for cardiac events and hypersensitivity reactions. The survey also queried for local (pain, redness, swelling) and systemic (fever, fatigue, headache, diarrhea, myalgia, chills, and vomiting) symptoms. Symptoms were graded as mild ("does not interfere with activity"); moderate ("some interference with activity"); or severe ("prevents daily activity"). Breakthrough SARS-CoV-2 infections were defined as either self-reported new diagnosis of COVID-19 or anti-N seroconversion. Breakthroughs were ascertained by surveys at 7 days following each T+C injection, as well as via unsolicited participant self-report. As part of the larger COVID-19 observational study of SARS-CoV-2 vaccine response, participants were

highly encouraged to report COVID-19 diagnosis or adverse events via multiple communications throughout the span of the study.

3. Results:

3.1: Demographics and vaccination history

Of 61 included participants, 21 received a single 300+300mg T+C dose and 40 received two 150+150mg doses. Median (interquartile range [IQR]) age was 62.5 (57.7-68.5) years, 36 (59%) participants were female, and 7 (11%) were non-white. The majority, 32 (52%), were kidney transplant recipients and 16 (26%) were thoracic transplant recipients (8 [13%] heart and 8 [13%] lung). The median time from transplant to T+C administration was 4.9 (2.2-11.1) years. For participants receiving a single 300+300mg T+C, the median follow-up time was 13 (7, 15) days post-T/C. For participants receiving two 150+150mg T+C, the median follow-up time was 45.5 (29, 61.5) days and 13.5 (7.5, 25) days post first and second 150+150mg T+C injection, respectively. The majority, 32 (52%), reported taking triple immunosuppression, defined as calcineurin inhibitor, antimetabolite, and corticosteroids. All participants had completed at least a three-dose primary series of SARS-CoV-2 vaccination pre-T+C, including 38 who received four doses and 5 who received five doses. All participants received either an mRNA vaccine (BNT162b2 or mRNA-1273) or Ad.26.COV2.S as a third dose. 54/61 (88%) participants received mRNA vaccine for all three doses of primary series; 36/38 (95%) and 5/5 (100%) participants received mRNA vaccine as fourth and fifth dose, respectively. Of the 22 participants stratified by pre-defined SARS-CoV-2 antigen exposure, 16 received SARS-CoV-2 vaccine <30 days pre-

T+C, 3 received SARS-CoV-2 vaccine after T+C injection, and 3 reported SARS-CoV-2 infection <90 days pre-T+C (**Table 1**).

3.2: Change in binding antibody

Following a full dose T+C, median (IQR) anti-RBD titer increased from 424 (<0.8, 2323) U/ml to 3500 (1433, 7115) U/ml on the clinical assay ($p<0.001$) (**Figure 1**); 16 (26%) participants had no detectable antibody on the clinical assay prior to T+C injection, all of whom seroconverted. The change in titer was similar for those receiving a single 300+300mg dose versus two 150+150mg doses (**Figure S1**). Anti-RBD titer on the research assay similarly increased, from median (IQR) 336.7 (8.1, 2858) to 8185 (6253, 10658) BAU ($p<0.001$) (**Table S1A**). There was similar change in anti-RBD titer among participants without recent antigen exposure ($n=39$), from median (IQR) anti-RBD 393 (<0.8, 3453) U/mL to 3638 (1363, 7115) U/mL on the clinical assay ($p<0.001$), and from 352.7 (IQR 10.2, 3422) BAU to 8029 (4894, 10658) BAU on the research assay ($p<0.001$) (**Table S1B**). There was a strong positive correlation between the clinical and research assay titers for all values below the upper limit of quantification of 4500 BAU (Spearman $\rho=0.84$, 76 samples, $n=51$) (**Figure S2**).

3.3: Change in surrogate neutralization

The proportion of participants who exhibited neutralizing inhibition ($\geq 20\%$) against the vaccine strain increased from 46% (28/61) pre-T+C to 100% (61/61) post full-dose T+C (Exact McNemar $p<0.001$). All participants exhibited neutralizing inhibition after T+C against the Alpha variant

(44% to 100%, $p < 0.001$), Beta variant (26% to 100%, $p < 0.001$) and Delta Variant (39% to 100%, $p < 0.001$) (**Tables S2A and S3A, Figure S3**).

In contrast, the proportion of participants who exhibited neutralizing inhibition against the Omicron BA.1 sublineage did not significantly increase: 8% (5/61) pre-T+C versus 16% (10/61) post full-dose T+C ($p = 0.06$). For the Omicron BA.2 sublineage, however, the proportion who exhibited neutralizing inhibition increased from 7% (4/61) to 72% (44/61) post-T+C ($p < 0.001$). Among the 39 participants without recent antigen exposure, changes in surrogate neutralization post-T+C were similar against tested variants (**Table S2B and S3B, Figure 2**).

3.4 Association between binding antibody and surrogate neutralization

There was a moderate positive correlation between anti-RBD titer and %ACE2 inhibition against the vaccine strain, alpha, beta, and delta variants (vaccine: $\rho = 0.65$, alpha: $\rho = 0.62$, beta: $\rho = 0.61$, delta $\rho = 0.62$). There was an attenuated correlation between anti-RBD and %ACE2 inhibition for Omicron sublineages, though most SOTRs who achieved neutralizing inhibition had high levels of anti-RBD after T+C: median (IQR) 7888 (2433, 10865) ($n = 10$) for BA.1 and 4696 (2027, 8688) for BA.2 ($n = 44$) (**Figure S4, Table S4**).

3.5 Impact of a second 150+150mg T+C dose on VOC neutralization

Among 40 participants who received two 150+150mg doses, the proportion reaching neutralizing inhibition against the vaccine strain increased from 43% (17/40) pre-T+C, to 97% (32/33) post-T+C dose 1, and 100% (40/40) post-T+C dose 2. The proportion reaching neutralizing inhibition against Omicron BA.1 did not increase: 10% (4/40) pre-T+C, to 6% (2/33)

post-T+C dose 1, and 10% (4/40) post-T+C dose 2. However, the proportion reaching neutralizing inhibition against Omicron BA.2 increased from 8% (3/40) pre-T+C, to 55% (18/33) post-T+C dose 1, and 80% (32/40) post-T+C dose 2 (**Figure S5**).

3.6 Safety and SARS-CoV-2 infections

Zero participants reported an adverse cardiac event, hypersensitivity reaction, or acute organ rejection within 7 days of any T+C injection. Reported reactions were mild or moderate and were more frequent after 300+300mg dosing versus 150+150mg dosing (**Figure S6**). There were no reported symptomatic breakthrough SARS-CoV-2 infections, though one participant showed anti-N seroconversion after a first 150+150mg dose of T+C, consistent with asymptomatic infection. The median (IQR) of follow-up after T+C was 13 (7, 19).

4. Discussion:

This real-world observational study of vaccinated SOTRs receiving T+C indicates that monoclonal antibody-based PrEP increases binding antibody responses and plasma neutralizing capacity against earlier VOCs, yet confirms variable effect against Omicron sublineages. Specifically, there was no observed improvement in BA.1 neutralization, with nearly 85% of recipients lacking neutralizing inhibition two weeks post-injection. In contrast, neutralizing activity against BA.2, the current dominant sublineage in the United States and Europe¹³, was augmented; 72% of T+C recipients reached neutralizing inhibition. In keeping with updated FDA recommendations, the impact of the increased 300+300mg dose was pronounced and may be necessary to achieve BA.2 neutralization for many SOTRs. Reassuringly, T+C was well-tolerated

and there were no early signals for serious adverse events including cardiac complications as described in the landmark PROVENT trial, though a future study of a longer timeframe would be necessary to determine longitudinal adverse events in SOTRs⁷.

Our data suggest that T+C is a reasonable adjunct to vaccination in SOTRs, yet may not provide universal protection against SARS-CoV-2 infection amid an evolving variant climate. Indeed, preliminary data indicates that breakthrough COVID-19 during the Omicron era has occurred in SOTRs despite full vaccination and T+C injection, particularly with BA.1 sublineages¹⁴.

Furthermore, long-term breakthrough post-TC against BA.2 needs to be investigated given the current dominance of BA.2 sublineage.

It is notable that common binding antibody assays are capable of detecting changes in anti-RBD levels following T+C injection and provide similar results. Consistent with prior work¹⁵, high levels of binding antibody were associated with Omicron neutralizing inhibition, which supports the role of antibody testing as one component of clinical decision-making regarding risk stratification and the timing of additional active or passive immunization (i.e., booster vaccinations and/or repeat T+C dosing).

A limitation of this study is that includes a small, heterogeneous sample. While this study aims to capture the real-life efficacy of T+C, the true effect of T/C is difficult to capture due to confounding factors from varying vaccination timeline, SARS-CoV-2 infection status, and other monoclonal antibody injections. Another limitation is the lack of long-term follow-up to assess rates of clinical breakthrough and safety. The study relied on participant surveys sent out a week after T+C doses and unsolicited patient self-reported to assess the safety and clinical breakthrough. Considering that preliminary safety and breakthrough data revealed events

months after injections, future studies should be conducted on the long-term safety and breakthrough rate of T+C, particularly in SOTRs as their interaction with T+C has been understudied.

T+C is a reasonable complementary strategy to vaccination in high-risk SOTRs to improve neutralizing capacity against select Omicron sublineages. Assessment of the real-world efficacy and safety of T+C in SOTR is of utmost importance, since SOTRs face heightened risks of severe illness or death from COVID-19 and since only few SOTRs were included in the PROVENT trial. Studies such as ours incorporating both clinical and laboratory data offer valuable insights into the real-world efficacy and safety of T+C in one of our most vulnerable population. Further research examining the durability of neutralization against emerging Omicron sublineages is necessary, especially with evolving mutations and potential immune evasion^{9,16}.

References:

1. Benotmane I, Bruel T, Planas D, Fafi-Kremer S, Schwartz O, Caillard S. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. *Kidney Int.* 2022.
2. Kamar N, Abravanel F, Marion O, et al. Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant. *JAMA Network Open.* 2021;4(11):e2136030-e2136030.
3. Karaba AH, Zhu X, Liang T, et al. A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. *American Journal of Transplantation.* 2022.
4. Qin CX, Moore LW, Anjan S, et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. *Transplantation.* 2021;105(11):e265-e266.
5. Sun J, Zheng Q, Madhira V, et al. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. *JAMA Internal Medicine.* 2022;182(2):153.
6. Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals [press release]. U.S. Food and Drug Administration, December 08, 2021 2021.

7. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. *New England Journal of Medicine*. 2022.
8. Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature*. 2022;602(7898):682-688.
9. FDA. Fact Sheet For Healthcare Providers: Emergency Use Authorization For Evusheld (tixagevimab co-packaged with cilgavimab). In: U.S. Food and Drug Administration; 2022.
10. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA*. 2021;325(17):1784.
11. William A. Werbel M, Brian J. Boyarsky, MD, PhD, Michael T. Ou, BS, Allan B. Massie, PhD, Aaron A.R. Tobian, MD, PhD, Jacqueline M. Garonzik-Wang, MD, PhD, Dorry L. Segev, MD, PhD. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. *Annals of Internal Medicine*. 2021;174(9):1330-1332.
12. Schober P, Boer C, Schwarte LA. Correlation Coefficients: Appropriate Use and Interpretation. *Anesthesia & Analgesia*. 2018;126(5):1763-1768.
13. CDC. COVID Data Tracker Variant Proportions. Centers for Disease Control and Prevention. <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>. Updated 5/3/22. Accessed May 6, 2022.
14. Benotmane I, Velay A, Vargas GG, et al. Breakthrough Covid-19 cases despite tixagevimab and cilgavimab (Evusheld™) prophylaxis in kidney transplant recipients. In: Cold Spring Harbor Laboratory; 2022.
15. Kumar D, Hu Q, Samson R, et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. *American Journal of Transplantation*. 2022.
16. Khan K, Karim F, Ganga Y, et al. Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity. In: Cold Spring Harbor Laboratory; 2022.

ACKNOWLEDGMENTS

The authors thank the participants of the Johns Hopkins COVID-19 Transplant Vaccine Study, without whom this research could not be possible. They also thank the members of the study team, including Brian J. Boyarsky MD, PhD; Laura Zeiser, MS; Chunyi Xia, BS; Kim Hall; Mary Sears, BS; Alex Alex; Jonathan Susilo.

DISCLOSURE

Dr Segev reports receiving consulting and/or speaking honoraria from Sanofi, Novartis, Veloxis, Mallinckrodt, Jazz Pharmaceuticals, CSL Behring, Thermo Fisher Scientific, Caredx, Transmedics, Kamada, MediGO, Regeneron, AstraZeneca, Takeda/Shire, and Bridge to Life. Dr. Avery has

grant/research support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, Regeneron, and Takeda/Shire. Dr. Karaba has received consulting fees from Roche. The remaining authors of this manuscript have no financial disclosures or conflicts of interest to disclose as described by the American Journal of Transplantation.

FUNDING/GRANT/AWARD INFORMATION

This work was supported by the Ben-Dov family, the Trokhan Patterson family, The ASTS Fryer Resident Scientist Award (Dr. Mitchell), grants 5T32DK007713 (Dr. Alejo), T32DK007732 (Dr. Chang), and K01DK101677 (Dr. Massie) from the National Institute of Diabetes and Digestive and Kidney Diseases; grant K24AI144954 (Dr. Segev), K08AI156021 (Dr. Karaba), U01AI138897, 3U01AI138897-04S1, and K23AI157893 (Dr. Werbel) from the National Institute of Allergy and Infectious Diseases; grant U54CA260491 (Dr. Pekosz, Dr. Karaba) from the National Cancer Institute.

Table 1. Clinical and demographic characteristics of SOTRs receiving Tixagevimab plus Cilgavimab

	Overall (N=61)	Recent Vaccination or COVID-19 (N=22)	No Recent Vaccination or COVID-19 (N=39)
Age, years (%)			
20-39	3 (5)	2 (9)	1 (3)
40-59	20 (33)	7 (32)	13 (33)
60-79	38 (62)	13 (59)	25 (64)
Female sex (%)	36 (59)	9 (41)	27 (69)
Nonwhite race (%)	7 (11)	2 (9)	5 (13)
Years since transplantation (IQR)	4.9 (2.2-11.1)	5.8 (2.3-11.7)	4.3 (2.1-11.1)
Graft transplanted (%)			
Kidney	32 (52)	9 (41)	23 (59)
Liver	5 (8)	0 (0)	5 (13)
Heart	8 (13)	5 (23)	3 (8)
Lung	8 (13)	6 (27)	2 (5)
Multi-organ	8 (13) ¹	2 (9) ²	6 (15) ³
Anti-rejection medications (%) ⁴			
Triple immunosuppression	32 (52)	11 (50)	21 (54)
CNI	54 (88)	20 (91)	34 (87)
Steroids	41 (67)	14 (64)	27 (69)
Mycophenolate	52 (85)	18 (82)	34 (87)
mTOR	8 (13)	5 (23)	3 (8)
Tacrolimus	49 (80)	17 (77)	32 (82)
Belatacept	2 (3)	0 (0)	2 (5)
Days since last vaccination (IQR)	82 (26-161)	20 (15-27)	116 (44-161)
Number of Vaccine Doses pre-T+C (%)			
Three	23 (38)	4 (18)	19 (49)

Four	33 (54)	17 (77)	16 (41)
Five	5 (8)	1 (5)	4 (10)
Received mRNA vaccine (%) ⁵			
Primary series ⁵	54/61 (88)	22/22 (100)	32/39 (82)
Fourth Dose	40/42 (95)	20/20 (100)	20/22 (91)
Fifth Dose	5/5 (100)	2/2(100)	3/3 (100)
Prior COVID-19 (%) ⁶	3 (5)	3 (14)	0 (0)
Recent COVID-19 vaccination (%) ⁷	20 (33)	20 (91)	0 (0)

¹ 2 kidney-liver, 4 kidney-pancreas, 1 kidney-heart, 1 lung-intestine

² 1 kidney-heart, 1 lung-intestine

³ 2 kidney-liver, 4 kidney-pancreas

⁴ anti-rejection medications are not mutually exclusive

⁵ Received mRNA all three doses

⁶ within 90 days pre-T+C

⁷ one participant received vaccination post-T+C

Abbreviations: CNI calcineurin inhibitor; mTOR mammalian target of rapamycin inhibitor

Table S1. Median Anti-RBD titers and %ACE2 inhibition of SARS-CoV-2 variants, by Tixagevimab and Cilgavemab dose

A. All participants

Comparison	150+150mg T+C			300+300mg T+C		
	40			61		
N						
	pre-T+C	2 weeks post-T+C	sign-rank p	pre-T+C	2 weeks post-T+C	sign-rank p
Clinical anti-RBD Ig	144.4 (<0.8, 2076)	1540 (656, 3096)	0.002	424.0 (<0.8, 2323)	3500 (1433, 7115)	<0.001
Research anti-RBD IgG	243.8 (6.6, 1813)	5399 (2548, 5939)	<0.001	336.7 (8.1, 2858)	8185 (6253, 10658)	<0.001
ACE2-vaccine (IQR)	13.1 (7.7, 50.5)	90.0 (65.6, 94.1)	<0.001	14.3 (7.2, 57.3)	98.3 (92.9, 99.1)	<0.001
%ACE2-alpha (IQR)	10.9 (5.4, 38.2)	88.3 (59.7, 91.9)	<0.001	12.2 (5.5, 45.7)	97.4 (90.5, 98.6)	<0.001
%ACE2-beta (IQR)	9.6 (4.5, 17.5)	80.9 (52.7, 84.5)	<0.001	9.4 (3.3, 22.3)	93.8 (80.8, 96.9)	<0.001
%ACE2-delta (IQR)	11.3 (5.3, 32.1)	85.6 (51.6, 91.4)	<0.001	11.9 (5.0, 37.7)	96.6 (90.6, 98.1)	<0.001
%ACE2-BA.1 (IQR)	4.7 (0.5, 11.6)	0.0 (0.0, 2.0)	0.01	4.6 (0.0, 10.5)	0.0 (0.0, 7.4)	0.4
%ACE2-BA.2 (IQR)	6.3 (0.0, 10.0)	21.0 (8.6, 32.2)	<0.001	2.7 (0.0, 9.6)	44.0 (17.4, 57.4)	<0.001

B. Patients who did not report COVID-19 exposure

	150+150mg T+C			300+300mg T+C		
	23			16		
N						
	pre-T+C (n=23)	2 weeks post-150+150 T+C (n=23)	sign-rank p	pre-T+C (n=39)	2 weeks post-300+300 T+C (n=39)	sign-rank p
Clinical anti-RBD Ig	134.9 (17.8, 2825)	1840 (595, 4568)	0.003	393 (<0.8, 3453)	3638 (1363, 7115)	<0.001
Research anti-RBD IgG	251.8 (10.2, 2858)	5429 (2302, 5855)	<0.001	352.7 (10.2, 3422)	8029 (4894, 10658)	<0.001
%ACE2-vaccine (IQR)	15.2 (5.8, 79.0)	90.4 (54.1, 94.1)	<0.001	16.1 (5.8, 79.0)	98.2 (90.4, 99.0)	<0.001
%ACE2-alpha (IQR)	10.1 (4.2, 59.0)	86.8 (57.5, 92.0)	<0.001	12.7 (5.3, 67.0)	97.4 (86.0, 98.6)	<0.001
%ACE2-beta (IQR)	9.6 (3.0, 39.8)	79.5 (50.2, 84.4)	<0.001	9.8 (3.1, 38.0)	93.6 (76.8, 96.9)	<0.001
%ACE2-delta (IQR)	10.1 (5.3, 48.1)	85.1 (45.2, 91.4)	<0.001	10.6 (4.9, 50.7)	96.3 (82.9, 98.1)	<0.001
%ACE2-BA.1 (IQR)	7.5 (1.8, 12.2)	0.0 (0.0, 1.0)	0.001	6.2 (1.8, 10.6)	0.1 (0.0, 10.1)	0.4
%ACE2-BA.2 (IQR)	7.5 (0.0, 9.7)	14.0 (7.9, 32.3)	0.02	5.5 (0.0, 9.6)	39.0 (13.0, 57.9)	<0.001

Table S2. Proportion of participants achieving $\geq 20\%$ ACE2 inhibition before and two weeks after 300-mg of Tixagevimab plus Cilgavimab, by SARS-CoV-2 variant

A. All participants

Variants of concern	Pre-T+C	2 weeks post-T+C	Exact McNemar (p-value)
Vaccine (ancestral, WA/1)	28/61 (46%)	61/61 (100%)	<0.001
Alpha (B.1.1.7)	27/61 (44%)	61/61 (100%)	<0.001
Beta (B.1.351)	16/61 (26%)	61/61 (100%)	<0.001
Delta (B.1.617.2)	24/61 (39%)	61/61 (100%)	<0.001
Omicron BA.1	5/61 (8%)	10/61 (16%)	0.06
Omicron BA.2	4/61 (7%)	44/61 (72%)	<0.001

B. Participants without reported recent SARS-CoV-2 antigen exposure

Variants of concern	Pre-T+C	2 weeks post-T+C	Exact McNemar (p-value)
Vaccine (ancestral, WA/1)	17/39 (44%)	39/39 (100%)	<0.001
Alpha (B.1.1.7)	17/39 (44%)	39/39 (100%)	<0.001
Beta (B.1.351)	12/39 (31%)	39/39 (100%)	<0.001
Delta (B.1.617.2)	15/39 (38%)	39/39 (100%)	<0.001
Omicron BA.1	3/39 (8%)	6/39 (15%)	0.25
Omicron BA.2	2/39 (5%)	26/39 (67%)	<0.001

Table S3. Median %ACE2 inhibition of participants achieving $\geq 20\%$ ACE2 inhibition before and two weeks after 300-mg of Tixagevimab plus Cilgavimab, by SARS-CoV-2 variant

A. All participants

Variants of concern	Pre-T+C (%)	2 weeks post-T+C (%)
Vaccine (ancestral, WA/1)	69.3 (43.6, 91.8) (n=28)	98.3 (92.9, 99.1) (n=61)
Alpha (B.1.1.7)	59.0 (33.5, 83.6) (n=27)	97.4 (26.5, 67.2) (n=61)
Beta (B.1.351)	47.8 (36.1, 68.4) (n=16)	93.8 (80.8, 96.9) (n=61)
Delta (B.1.617.2)	53.0 (32.1, 78.0) (n=24)	96.6 (90.6, 98.1) (n=61)
Omicron BA.1	29.6 (26.5, 67.2) (n=5)	37.0 (23.6, 56.9) (n=10)
Omicron BA.2	41.4 (29.8, 56.8) (n=4)	51.7 (39.7, 63.0) (n=44)

B. Participants without reported recent SARS-CoV-2 antigen exposure

Variants of concern	Pre-T+C (%)	2 weeks post-T+C (%)
Vaccine (ancestral, WA/1)	79.4 (51.5, 91.1) (n=17)	98.2 (90.4, 99.0) (n=39)
Alpha (B.1.1.7)	68.3 (40.6, 80.3) (n=17)	97.4 (86.0, 98.6) (n=39)
Beta (B.1.351)	47.8 (38.9, 63.1) (n=12)	93.6 (76.8, 96.9) (n=39)
Delta (B.1.617.2)	59.9 (41.4, 76.6) (n=15)	96.3 (82.9, 98.1) (n=39)
Omicron BA.1	26.5 (21.3, 29.6) (n=3)	29.5 (23.6, 40.7) (n=6)
Omicron BA.2	29.8 (26.3, 33.3) (n=2)	52.6 (39.0, 60.5) (n=26)

Table S4. Proportion of participants achieving neutralizing inhibition at select anti-RBD thresholds after 300-mg of Tixagevimab plus Cilgavimab, by SARS-CoV-2 variant

A. All participants

All participants	n	vaccine	BA.1	BA.2
0-499	5	53.8 (44.5, 97.4)	0 (0, 7.0)	13.0 (0, 44.0)
500-999	7	98.0 (88.1, 98.9)	0 (0, 0)	24.6 (0, 48.1)
1000-2499	13	95.5 (86.1, 98.3)	0 (0, 0)	35.8 (15.5, 47.8)
2500-4999	11	98.5 (88.9, 99.0)	2.4 (0, 14.3)	52.0 (17.4, 59.4)
5000-10000	16	98.3 (95.9, 99.2)	3.1 (0, 7.9)	45.2 (24.0, 62.4)
10000+	9	99.1 (98.3, 99.3)	10.1 (0, 23.6)	54.3 (50.1, 60.5)

B. Participants who reported SARS-CoV-2 exposure

	n	vaccine	BA.1	BA.2
0-499	0	n/a	n/a	n/a
500-999	3	98.0 (88.1, 98.3)	0 (0, 0)	24.6 (0, 48.1)
1000-2499	8	96.5 (88.3, 98.5)	0 (0, 0)	39.7 (17.1, 49.2)
2500-4999	3	98.5 (88.9, 99.2)	0.7 (0, 14.4)	51.2 (17.4, 66.0)
5000-10000	3	99.1 (99.1, 99.6)	4.2 (2.6, 56.9)	57.4 (56.9, 90.1)
10000+	5	98.4 (98.1, 99.6)	0 (0, 81.7)	53.0 (44.5, 65.5)

C. Participants who did not report SARS-CoV-2 exposure

	n	vaccine	BA.1	BA.2
0-499	5	53.8 (44.5, 97.4)	0 (0, 7.0)	13.0 (0, 44.0)
500-999	4	94.6 (83.3, 99.2)	0 (0, 12.9)	19.8 (4.3, 56.3)
1000-2499	5	94.7 (86.1, 98.3)	0 (0, 0)	24.6 (15.5, 35.8)
2500-4999	8	98.5 (88.6, 98.9)	3.2 (0, 10.9)	52.6 (24.3, 58.6)
5000-10000	13	97.8 (95.1, 98.8)	0.4 (0, 5.6)	39.0 (19.6, 54.4)
10000+	4	99.2 (98.7, 99.3)	12.7 (5.0, 19.4)	57.1 (52.2, 60.2)

Figure 1. Anti-RBD level before and two weeks after 300+300mg of Tixagevimab plus Cilgavimab






Figure 2. Change in ACE2 inhibition versus SARS-CoV-2 variants after 300+300mg of Tixagevimab plus Cilgavimab injection

A. Ancestral Variant



B. BA.1




* Participant had suspected asymptomatic COVID-19 (anti-N seroconversion), as well as intercurrent COVID-19 vaccination.

+ Participant reported COVID-19 30 days prior to first T+C dose.

^ participant reported COVID-19 68 days prior to first T+C dose.

C. BA.2




* Participant had suspected asymptomatic COVID-19 (anti-N seroconversion), as well as intercurrent COVID-19 vaccination.

+ Participant reported COVID-19 68 days prior to first dose.

Figure S1. Anti-RBD level before and two weeks after 300+300mg of Tixagevimab plus Cilgavimab, by dose administration

A. Participants Receiving Two 150+150mg Doses



B. Participants Receiving a Single 300+300mg Dose






Figure S2. Correlation between clinical and research anti-RBD assays in vaccinated SOTRs following Tixagevimab and Cilgavimab injection




Correlation was performed only for samples between upper and lower limit of detection on both assays (76 samples, n=51); if using all samples: $\rho = 0.65$ (176 samples, n=61); if limited to post-injection samples below the upper limited of quantification: $\rho = 0.65$ (26 samples, n=15); if using all post-injection samples: $\rho = 0.43$ (115 samples, n=61)

Figure S3. Change in ACE2 inhibition versus SARS-CoV-2 variants after Tixagevimab plus Cilgavimab Injection

A. Alpha (B.1.1.7)



B. Beta (B.1.351)



C. Delta (B.1.617.2)






Figure S4. Association between surrogate neutralization of SARS-CoV-2 variants and anti-RBD level before and after Tixagevimab and Cilgavimab Injection


A. Ancestral variant




B. Omicron BA.1




C. Omicron BA.2




D. Alpha



E. Beta




F. Delta




Increasing anti-RBD titer after T+C moderately correlated with increasing %ACE2 inhibition ($p=0.43$) against the vaccine strain. Using all 176 samples from 61 participants before and after injection, the correlation between anti-RBD and %ACE2 inhibition against BA.1: $p=0.04$, BA.2: $p=0.40$, alpha: $p=0.62$, beta: $p=0.61$, delta: $p=0.62$. Using only the 115 post-T+C samples from 61 participants, the correlation between anti-RBD and %ACE2 inhibition against BA.1: $p=0.32$, BA.2: $p=0.39$, alpha: $p=0.40$, beta: $p=0.41$, delta: $p=0.41$

Figure S5. Change in ACE2 inhibition versus SARS-CoV-2 variants following first and second 150+150mg doses of Tixagevimab plus Cilgavimab

A. Ancestral variant




B. Omicron BA.1



* Participant had suspected asymptomatic COVID-19 (anti-N seroconversion), as well as recent COVID-19 vaccination.

+ Participant reported COVID-19 30 days prior to first T+C dose.


C. Omicron BA.2



* Participant had suspected asymptomatic COVID-19 (anti-N seroconversion), as well as recent COVID-19 vaccination.

+ Participant reported COVID-19 30 days prior to first T+C dose.

Figure S6. Self-reported local and systemic adverse reactions after Tixagevimab plus Cilgavimab Injection, by dose administration.



Responses were received from 60/61 (98%) of participants. Some surveys were incomplete in documenting degree of redness (n=1), fatigue (n=1), myalgia (n=2).